Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21489525 | 0.82 | GLO1 (0.59) | GLO1ALOX15HTTKEAP1MMP2 | |
| SCHEMBL5886600 | 0.77 | KDM1A (0.42) | GLO1ALOX15HTTKEAP1MMP2 | |
| SCHEMBL17199220 | 0.76 | GLO1 (0.47) | GLO1ALOX15HTTKEAP1MMP2 | |
| SCHEMBL30936970 | 0.76 | GLO1 (0.66) | GLO1ALOX15HTTKEAP1MMP2 | |
| SCHEMBL2068498 | 0.74 | KEAP1 (0.65) | GLO1ALOX15HTTKEAP1NFE2L2 | |
| SCHEMBL29904739 | 0.74 | KEAP1 (0.65) | GLO1ALOX15HTTKEAP1NFE2L2 | |
| Phenazine SCHEMBL1750964 | 0.72 | MAPT (0.58) | ALDH1A1L3MBTL1CYP1A2CYP2C9MAPT | |
| SCHEMBL6862410 | 0.72 | GLO1 (1.00) | GLO1ALOX15HTTALDH1A1MAPT | |
| SCHEMBL2295132 | 0.72 | MAPT (0.56) | ALDH1A1L3MBTL1CYP1A2CYP2C9MAPT | |
| SCHEMBL29941063 | 0.72 | GLO1 (1.00) | GLO1ALOX15HTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024735-B2 | Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same | ROCHE DIABETES CARE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024735-B2 | Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same | ROCHE DIABETES CARE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-11230727-B2 | Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same | ROCHE DIABETES CARE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3131882-B1 | PHENAZINIUM MEDIATORS | ROCHE DIAGNOSTICS GMBH (DE) | 2020-07-15 | — | — | EP | disclosed |
| US-20190233870-A1 | DETECTION REAGENTS AND ELECTRODE ARRANGEMENTS FOR MULTI-ANALYTE DIAGNOSTIC TEST ELEMENTS, AS WELL AS METHODS OF USING THE SAME | ROCHE DIABETES CARE, INC. | 2019-08-01 | — | — | US | disclosed |
| US-9988358-B2 | Phenazinium mediators | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988358-B2 | Phenazinium mediators | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| WO-2018067235-A1 | DETECTION REAGENTS AND ELECTRODE ARRANGEMENTS FOR MULTI-ANALYTE DIAGNOSTIC TEST ELEMENTS, AS WELL AS METHODS OF USING THE SAME | ROCHE DIABETES CARE, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20170226068-A1 | PHENAZINIUM MEDIATORS | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226068-A1 | PHENAZINIUM MEDIATORS | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-10 | — | — | US | disclosed |
| EP-3131882-A1 | PHENAZINIUM MEDIATORS | Roche Diagnostics GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015158645-A1 | PHENAZINIUM MEDIATORS | ROCHE DIAGNOSTICS GMBH (DE) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015158645-A1 | PHENAZINIUM MEDIATORS | ROCHE DIAGNOSTICS GMBH (DE) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226068-A1 | PHENAZINIUM MEDIATORS | IL5, TRPV5, TRPM5 | GLO1 322/4885ALOX15 969/4885HTT 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.